skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pleiotropic effects of statins in atrial fibrillation patients: the evidence

Review

(3151) Views  (1237) Full article downloads

Authors: Hadi AR Hadi, Wael Al Mahmeed, Jassim Al Suwaidi, Samer Ellahham

Published Date June 2009 Volume 2009:5 Pages 533 - 551
DOI: http://dx.doi.org/10.2147/VHRM.S4841

Hadi AR Hadi, Wael Al Mahmeed, Jassim Al Suwaidi, Samer Ellahham

Institute of Cardiac Sciences, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates

Abstract: Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice. The understanding of the pathophysiology of AF has changed during the last several decades, and a significant role of inflammation and of the renin–angiotensin–aldosterone system has been postulated both experimentally and clinically. There is emerging evidence of an association between inflammation and AF, and mounting evidence links increased C-reactive protein levels not only to already existing AF but also to the risk of developing future AF. The beneficial effects of statins on AF have been reported in several studies. Several randomized clinical and large observational studies have shown similar result that show the beneficial effect of statins in AF. In clinical studies, statins were considered effective in preventing AF after electrical cardioversion, post-ablation, and after permanent pacemaker and implantable cardioverter defibrillator insertion. The antiarrhythmic mechanisms of statins regarding AF prevention in patients with heart failure are still not clear. Perioperative statin use has been associated with favorable postoperative outcome in both cardiovascular and noncardiovascular conditions. Despite a growing body of evidence that drugs with anti-inflammatory properties such as statins may prevent AF, the observed positive effects of statins on the burden of AF appeared to be independent of their cholesterol-reducing properties. However, further data from large-scale randomized trials are clearly needed.

Keywords: statins, pleiotropic effects, atrial fibrillation






 

Other articles by Dr Har Khafaji Hadi



Readers of this article also read:

Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Dronedarone for atrial fibrillation: a new therapeutic agent
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk
Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals
Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy
Atorvastatin in stroke: a review of SPARCL and subgroup analysis
Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University